Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Abionyx Pharma SA    ABNX   FR0012616852

ABIONYX PHARMA SA

(ABNX)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Abionyx Pharma : Cash position and activity update for Q3 2019

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/24/2019 | 01:22pm EST

Press Release

Cash position and activity update for Q3 2019

  • Cash position of €8.8 million at 30 September 2019

Toulouse, FRANCE, Lakeland, UNITED-STATES, October 24, 2019, 6:00pm CEST - ABIONYX Pharma

(FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, announces today that cash and cash equivalents totaled €8.8 million at September 30, 2019.

The activities of ABIONYX Pharma are focused on the discovery and development of innovative therapies to improve the lives of patients; the company did not generate any revenues in the first nine months of the year, as expected.

The recent evolution of governance, combined with the Company's financial resources, makes it possible to make progress in the formalization of a new strategy while having greater visibility. A strategic and detailed review of the assets of the company is underway, based on important proprietary clinical data in cardiovascular and metabolic diseases. Possible collaborations with external partners are under consideration, and the company is committed to communicating a new strategic development plan by the end of the first quarter of 2020.

About ABIONYX Pharma

ABIONYX Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients. The biotech assets inherited from CERENIS Therapeutics constitute a rich portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as a HDL targeted drug delivery platform in immuno-oncology and chemotherapy, and in other non-oncological molecules.

Contacts

NewCap

NewCap

Investor relations

Media relations

Louis-Victor Delouvrier

Nicolas Merigeau

abionyx@newcap.eu

abionyx@newcap.eu

+33 (0)1 44 71 98 53

+33 (0)1 44 71 94 98

1/1

Disclaimer

Abionyx Pharma SA published this content on 24 October 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 October 2019 17:21:01 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABIONYX PHARMA SA
10/31ABIONYX PHARMA SA : Monthly statement on outstanding equity shares and voting ri..
CO
10/24ABIONYX PHARMA : Cash position and activity update for Q3 2019
PU
10/24ABIONYX PHARMA SA : 3rd quarter earnings
CO
08/31ABIONYX PHARMA SA : Monthly statement on outstanding equity shares and voting ri..
CO
08/27ABIONYX PHARMA SA : Change of company name
CO
08/26ABIONYX PHARMA SA : Nomination
CO
07/31ABIONYX PHARMA SA : Monthly statement on outstanding equity shares and voting ri..
CO
06/30ABIONYX PHARMA SA : Monthly statement on outstanding equity shares and voting ri..
CO
06/24ABIONYX PHARMA SA : Proxy Statments
CO
05/31ABIONYX PHARMA SA : Monthly statement on outstanding equity shares and voting ri..
CO
More news
Financials (EUR)
Sales 2019 -
EBIT 2019 -4,43 M
Net income 2019 -0,59 M
Finance 2019 4,95 M
Yield 2019 -
P/E ratio 2019 -13,3x
P/E ratio 2020 -1,05x
EV / Sales2019 infx
EV / Sales2020 infx
Capitalization 7,82 M
Chart ABIONYX PHARMA SA
Duration : Period :
Abionyx Pharma SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABIONYX PHARMA SA
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 0,40  €
Last Close Price 0,36  €
Spread / Highest target 38,9%
Spread / Average Target 11,1%
Spread / Lowest Target -16,7%
EPS Revisions
Managers
NameTitle
Cyrille Tupin Chief Executive Officer & Director
Emmanuel Huynh Chairman
Constance Keyserling Senior Vice President-Clinical Development
Renee Benghozi Chief Medical Officer
Jean-Louis Dasseux Director
Sector and Competitors
1st jan.Capitalization (M$)
ABIONYX PHARMA SA-26.53%8
GILEAD SCIENCES5.40%84 448
VERTEX PHARMACEUTICALS34.61%57 578
REGENERON PHARMACEUTICALS-1.38%40 446
WUXI APPTEC CO., LTD.68.15%20 724
GENMAB49.32%15 646